Larvol Delta - Alzamend-Neuro-Announces-the-Initiation-of-a-Phase-IIIA-Trial-for-Its-Immunotherapy-Vaccine-ALZN002-to-Treat-Mild-to-Moderate-Dementia-of-the-Alzheimers-Type

ALZN002 - Alzamend Neuro

https://www.businesswire.com/news/home/20230403005570/en/Alzamend-Neuro-Announces-the-Initiation-of-a-Phase-IIIA-Trial-for-Its-Immunotherapy-Vaccine-ALZN002-to-Treat-Mild-to-Moderate-Dementia-of-the-Alzheimer%E2%80%99s-Type

Apr 3, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next